Dopamine agonists crossover study

Dopamine agonists crossover study - DACS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002163

Enrollment

Registered

2009-07-07

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Overnight switch from PPX to ROP at dose ratio 3:10. Evaluation at 0, 2, 4, 8 weeks. Overnight switch from ROP to PPX at dose ratio 10:3. Evaluation at 0, 2, 4, 8 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient Parkinson's disease patients whose clinical symptoms are well medically controlled.

Exclusion criteria

Exclusion criteria: Those who cannot give an effective informed consent.

Design outcomes

Primary

Measure	Time frame
MDS-UPDRS, ESS(Epworth Sleepiness Scale), SHAPS(Snaith-Hamilton Pleasure Scale). Biochemical laboratory tests.	—

Countries

Japan

Contacts

Public ContactSatoshi Kaneko

Kansai Medical University Neurology

kanekosa@hirakata.kmu.ac.jp072-804-2540

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026